

Genesis Biotechnology partners with Yale University

31 October 2018 | News

Collaboration aims to accelerate the development and translation of Yale's research and innovation projects to a decision point



Genesis Biotechnology Group (GBG) and its CRO arm Genesis Drug Discovery & Development (GD³) has announced that it has entered into a partnership with Yale University to offer an integrated portfolio of drug discovery services from "target validation" to "lead optimization" to the awardees of the Blavatnik Fund for Innovation. The partnership is a part of GD³'s efforts to offer early drug discovery-based services to Yale's researchers, allowing their breakthrough research to get to the market as new drugs and treatments.

"We are delighted to partner with Yale University to accelerate the transition of fundamental biomedical discoveries into commercialization opportunities," said Olesia Buiakova, M.D., Ph.D., Chief Scientific Officer of GD³. "Our partnership with Yale is an important step forward for this program and we look forward to developing a strong and mutually beneficial relationship with the Blavatnik Fund and Office of Cooperative Research at Yale."

This partnership was made possible by a grant from the Blavatnik Family Foundation. This multi-year grant supports the Blavatnik Fund for Innovation at Yale, which was designed to bridge the gap between life science research and business and support faculty in the commercialization of applied research and technology. The fund's recent commitment of\$25 million has created new opportunities for emerging ventures and biotech companies.

"Genesis Biotechnology Group has been a true collaborator for innovation. Since initiating this relationship, GBG has invested an unparalleled level of engagement with our investigators and we are excited to see this collaboration grow for years to come," said William Wiesler, Ph.D., M.B.A., Director of the Blavatnik Fund and Director of New Ventures at the Yale Office of Cooperative Research (OCR). "We're incredibly excited about the work ahead to advance drug discoveries and we're looking forward to the increase in opportunities for ventures in life sciences as afforded by the Blavatnik Fund."